The oncogene DEK promotes leukemic cell survival and is downregulated by both nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells

Clinical Cancer Research

Volumn 16, Issue 6, 2010, Pages 1824-1833

  Secchiero, Paola ^a   Voltan, Rebecca ^a   Di Iasio, Maria Grazia ^a   Melloni, Elisabetta ^a   Tiribelli, Mario ^b   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHLORAMBUCIL; DEK PROTEIN; MESSENGER RNA; NUTLIN 3; ONCOPROTEIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CELL LEVEL; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOBLASTOID CELL; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; RNA INTERFERENCE; WILD TYPE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHLORAMBUCIL; CHROMOSOMAL PROTEINS, NON-HISTONE; DOWN-REGULATION; FEMALE; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS; PIPERAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEREOISOMERISM; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949769792     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3031     Document Type: Article

References (39)

1. Kappes F, Burger K, Baack M, Fackelmayer FO, Gruss C. Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 2001;276:26317-23.
2. Waldmann T, Baack M, Richter N, Gruss C. Structure-specific binding of the proto-onco- gene protein DEK to DNA. Nucleic Acids Res 2003;31:7003-10.
3. von Lindern M, Fornerod M, van Baal S, et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, DEK and CAN, and the expression of a chimeric, leukemia-specific DEK-CAN mRNA. Mol Cell Biol 1992;12: 1687-97.
4. Shearer BM, Knudson RA, Flynn HC, Ketterling RP. Development of a D-FISH method to detect DEK/CAN fusion resulting from t(6;9) (p23;q34) in patients with acute myelogenous leukemia. Leukemia 2005;19:126-31.
5. Aalto Y, El-Rifai W, Vilpo L, et al. Distinct gene expression profling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia 2001; 15:1721-8.
6. Sitwala KV, Mor-Vaknin N, Markovitz DM. Minireview: DEK and gene regulation, oncogenesis and AIDS. Anticancer Res 2003;23: 2155-8.
7. Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z. DEK overexpression in uterine cervical cancers. Pathol Int 2008;58:378-82.
8. Han S, Xuan Y, Liu S, et al. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int 2009;59: 443-7.
9. Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R, Gruss C. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev 2000;14:1308-12.
10. Soares LM, Zanier K, Mackereth C, Sattler M, Valcarcel J. Intron removal requires proofreading of U2AF/3′ splice site recognition by DEK. Science 2006;312:1961-5.
11. Campillos M, Garcia MA, Valdivieso F, Vazquez J. Transcriptional activation by AP-2 α is modulated by the oncogene DEK. Nucleic Acids Res 2003;31:1571-5.
12. Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, Ashburner BP. Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem 2006;281: 26802-12.
13. Faulkner NE, Hilfinger JM, Markovitz DM. Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site. J Biol Chem 2001;276:25804-12.
14. Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 2007;14:548-55.
15. Kappes F, Scholten I, Richter N, Gruss C, Waldmann T. Functional domains of the ubiquitous chromatin protein DEK. Mol Cell Biol 2004;24:6000-10.
16. Mor-Vaknin N, Punturieri A, Sitwala K, et al. The DEK nuclear auto-antigen is a secreted chemotactic factor. Mol Cell Biol 2006;26: 9484-96.
17. Wise-Draper TM, Morreale RJ, Morris TA, et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 2009;174:71-81.
18. Wise-Draper TM, Allen HV, Thobe MN, et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 2005;79:14309-17.
19. Kim DW, Chae JI, Kim JY, et al. Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. J Cell Biochem 2009;106:1048-59.
20. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006;26: 7506-19.
21. Khodadoust MS, Verhaegen M, Kappes F, et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009;69:6405-13.
22. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French cooperative group on chronic lymphocytic leukemia. N Engl J Med 1998;338:1506-19.
23. Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-91.
24. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:4122-9.
25. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006;107:4109-14.
26. Kojma K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006;108:993-1000.
27. Secchiero P, Corallini F, Gonelli A, et al. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 2007;100:61-9.
28. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584-93.
29. Secchiero P, Melloni E, di Iasio MG, et al. Nutlin-3 upregulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feed-back anti-apoptotic mechanism. Blood 2009;113:4300-8.
30. Milani D, Zauli G, Rimondi E, et al. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 2003;86:126-35.
31. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S. Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 1996;271:22961-4.
32. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 2008;14:2100-10.
33. Michael D, Oren M. The p53-2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
34. Kappes F, Fahrer J, Khodadoust MS, et al. DEK is a poly(ADPRibose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 2008;28:3245-57.
35. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31.
36. Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005;280:19166-76.
37. Steele AJ, Prentice AG, Hoffbrand AV, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood 2008;112:3827-34.
38. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
39. Mitani N, Niwa Y, Okamoto Y. Surveyor nucleare-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem 2007;44:557-9.